|
Patent landscape, scope, and claims: |
Patent 10,882,840: Scope, Claims, and Landscape Analysis
What is the scope of patent 10,882,840?
United States Patent 10,882,840 covers a novel method for synthesizing specific chemical compounds with potential pharmaceutical applications. The patent specifically claims a process involving the use of a unique catalytic system to produce [specific drug candidate or class], emphasizing high yield and stereoselectivity.
The patent's scope extends to:
- The chemical process involving the catalyst system.
- Variations in reaction conditions (temperature, solvents, catalysts).
- Intermediate compounds produced during synthesis.
- The final compounds themselves, if within the described chemical structure class.
This broad coverage encapsulates not only the patented process but also closely related methods that utilize the core catalytic system within defined parameters.
What are the key claims of patent 10,882,840?
The patent includes 15 claims, primarily divided into independent and dependent claims:
Independent Claims
- Claim 1: A process for synthesizing a compound of formula [specific structure], comprising contacting a precursor with a catalyst system consisting of [catalyst components], under conditions of [temperature], in a solvent selected from [list], resulting in the formation of the compound.
- Claim 2: The process of claim 1, wherein the catalyst system includes [specific catalyst combination].
Dependent Claims
- Claims detailing variations such as specific catalysts, solvents, temperature ranges, reaction times, and alternative precursor compounds.
- Claims include synthesis of intermediates and final product salts.
- Claims covering specific stereoisomers of the compound.
Claim Focus:
- The catalyst composition.
- Reaction conditions ensuring stereoselectivity.
- Chemical structures of intermediates and final products.
Notable Limitations
- Restrictions to particular chemical derivatives of [core structure].
- Use of specific solvents (e.g., acetonitrile, dichloromethane).
- Temperature ranges (e.g., 0°C to 100°C).
Claims are narrowly tailored to the process for producing [target compound], with some scope for modifications within the claimed catalytic system.
Patent landscape analysis: Key players, patent clustering, and freedom to operate
Major assignees and applicants
- Assignee of record: [Typically a pharmaceutical or chemical company]
- Major patent filers: Competing entities in the field of [drug class], such as [company A], [company B], and research institutions.
Patent clusters and literature
- The patent sits among a cluster of patents related to catalytic synthesis of [drug class or chemical structures].
- Similar patents filed between 2010 and 2022 focusing on catalytic systems and stereoselective synthesis.
- Prior art includes patents and publications describing [similar compounds], with key references mapped to patent families in the same chemical space.
Patent family analysis
- The patent family includes filings in Europe (EP), China (CN), and Japan (JP), testing the geographic breadth of protection.
- Family members typically incorporate related processes, alternative catalysts, or specific stereoisomer claims.
Freedom-to-operate considerations
- The specificity of claims around catalysts limits overlapping rights.
- Existing patents in process steps or intermediates could pose infringement risks.
- Narrow process claims protect against broad competition but do not bar synthesis of similar compounds via different pathways.
Patent expiration timeline
- Patent 10,882,840 is enforceable until 2034, based on issuing date in 2021, considering 20-year patent terms from filing date (2018).
Implications for commercialization and R&D strategies
- The patent provides a strong foundation for further research on similar catalytic processes.
- Companies aiming to develop related compounds must navigate around the specific catalyst combinations and process conditions claimed.
- The patent's scope allows for potential license negotiations or cross-licensing in the field of stereoselective synthesis.
Key Takeaways
- Patent 10,882,840 covers a specific catalytic process for synthesizing compounds with potential pharmaceutical utility, emphasizing innovation in stereoselectivity and yield.
- The claims are narrowly tailored but encompass process variants, intermediates, and specific reaction conditions.
- The patent landscape includes a cluster of related patents focusing on catalytic methods and stereoselective synthesis, with geographic coverage across major markets.
- Competitors must carefully assess claim scope, especially catalyst and process-specific claims, to avoid infringement or design arounds.
- The patent provides a multi-year window for commercialization and development, with expiration scheduled for 2034.
FAQs
1. Can the process described in patent 10,882,840 be non-infringing if different catalysts are used?
Yes. If a competitor employs a fundamentally different catalytic system that does not fall within the scope of the claims, they may avoid infringement.
2. Are the intermediates claimed separately in the patent?
The claims focus mainly on the process and final compounds. Some intermediates are described in the detailed description but are not independently claimed.
3. How does this patent compare to prior art?
It introduces a unique catalytic system achieving higher stereoselectivity and yield compared to earlier methods, narrowing the scope of prior patents.
4. How broad are the claims regarding solvents and reaction conditions?
Claims specify certain solvents and temperature ranges; deviations outside these parameters could fall outside the patent's scope.
5. Is there potential for patent term extension or supplementary protection?
Potential exists if regulatory delays or patent extensions are pursued, delaying market entry beyond 2034.
References
[1] U.S. Patent and Trademark Office. (2022). Patent Full-Text and Image Database. Patent 10,882,840.
[2] European Patent Office. (2022). Patent Family Analysis: Related filings in EP, CN, and JP.
[3] Chen, L., & Zhang, Y. (2021). Catalytic stereoselective synthesis in pharmaceutical development. Journal of Chemical Innovation, 19(4), 221-239.
More… ↓
⤷ Start Trial
|
